OBJECTIVE: To evaluate YKL-40 and MMP-9 proteins as tumor biomarkers in serum samples from patients with primary central nervous system lymphoma (PCNSL). METHODS: In this prospective longitudinal study, serum samples from consecutive patients with histologically confirmed PCNSL were collected concurrently with magnetic resonance imaging (MRI) scans at multiple time points and were analyzed for levels of YKL-40 and MMP-9 by enzyme-linked immunosorbent assay. Marker levels were correlated to disease status and survival. RESULTS: Forty-five patients with PCNSL were accrued. Median follow-up for survivors was 25 months, and 21 (47%) died during the study. A total of 230 serum samples were collected, and 93% had corresponding MRI scans. PCNSL patients without evidence of radiographic disease (29 patients, 131 samples) had significantly lower levels of serum YKL-40 and MMP-9 than patients with active tumor (n = 34 patients, 84 samples; p = 0.03 and 0.01, respectively). There was a significant inverse correlation between survival and doubling of the YKL-40 level (hazard ratio, 1.7; p = 0.01). INTERPRETATION: In patients with PCNSL, serum levels of YKL-40 and MMP-9 are associated with radiographic disease status. Longitudinal increase in serum levels of YKL-40, but not MMP-9, predicts survival in patients with PCNSL.
OBJECTIVE: To evaluate YKL-40 and MMP-9 proteins as tumor biomarkers in serum samples from patients with primary central nervous system lymphoma (PCNSL). METHODS: In this prospective longitudinal study, serum samples from consecutive patients with histologically confirmed PCNSL were collected concurrently with magnetic resonance imaging (MRI) scans at multiple time points and were analyzed for levels of YKL-40 and MMP-9 by enzyme-linked immunosorbent assay. Marker levels were correlated to disease status and survival. RESULTS: Forty-five patients with PCNSL were accrued. Median follow-up for survivors was 25 months, and 21 (47%) died during the study. A total of 230 serum samples were collected, and 93% had corresponding MRI scans. PCNSLpatients without evidence of radiographic disease (29 patients, 131 samples) had significantly lower levels of serum YKL-40 and MMP-9 than patients with active tumor (n = 34 patients, 84 samples; p = 0.03 and 0.01, respectively). There was a significant inverse correlation between survival and doubling of the YKL-40 level (hazard ratio, 1.7; p = 0.01). INTERPRETATION: In patients with PCNSL, serum levels of YKL-40 and MMP-9 are associated with radiographic disease status. Longitudinal increase in serum levels of YKL-40, but not MMP-9, predicts survival in patients with PCNSL.
Authors: Christina Cintin; Julia S Johansen; Ib Jarle Christensen; Paul A Price; Steen Sørensen; Hans Jørgen Nielsen Journal: Cancer Date: 2002-07-15 Impact factor: 6.860
Authors: Lauren E Abrey; Leah Ben-Porat; Katherine S Panageas; Joachim Yahalom; Brian Berkey; Walter Curran; Christopher Schultz; Steven Leibel; Diana Nelson; Minesh Mehta; Lisa M DeAngelis Journal: J Clin Oncol Date: 2006-11-20 Impact factor: 44.544
Authors: Lauren E Abrey; Tracy T Batchelor; Andrés J M Ferreri; Mary Gospodarowicz; Elisa J Pulczynski; Emanuele Zucca; Justine R Smith; Agnieszka Korfel; Carole Soussain; Lisa M DeAngelis; Edward A Neuwelt; Brian Patrick O'Neill; Eckhard Thiel; Tamara Shenkier; Fransesc Graus; Martin van den Bent; John F Seymour; Philip Poortmans; James O Armitage; Franco Cavalli Journal: J Clin Oncol Date: 2005-06-13 Impact factor: 44.544
Authors: Sushmita Roy; S Andrew Josephson; Jane Fridlyand; Jon Karch; Cigall Kadoch; Juliana Karrim; Lloyd Damon; Patrick Treseler; Sandeep Kunwar; Marc A Shuman; Ted Jones; Christopher H Becker; Howard Schulman; James L Rubenstein Journal: J Clin Oncol Date: 2007-12-03 Impact factor: 44.544
Authors: Jong Hyung Yoon; Hyoung Jin Kang; Hyery Kim; Ji Won Lee; June Dong Park; Kyung Duk Park; Hee Young Shin; Hyo Seop Ahn Journal: J Korean Med Sci Date: 2012-10-30 Impact factor: 2.153
Authors: H M C Shantha Kumara; David Gaita; Hiromichi Miyagaki; Xiaohong Yan; Sonali Ac Hearth; Linda Njoh; Vesna Cekic; Richard L Whelan Journal: World J Gastrointest Oncol Date: 2016-08-15
Authors: B Kornblit; T Wang; S J Lee; S R Spellman; X Zhu; K Fleischhauer; C Müller; M R Verneris; K Müller; J S Johansen; L Vindelov; P Garred Journal: Bone Marrow Transplant Date: 2016-07-18 Impact factor: 5.483
Authors: Elisabeth Schorb; Benjamin Kasenda; Johannes Atta; Stephan Kaun; Anke Morgner; Georg Hess; Thomas Elter; Nikolas von Bubnoff; Martin Dreyling; Mark Ringhoffer; Stefan W Krause; Günter Derigs; Beate Klimm; D Niemann; Kristina Fritsch; Jürgen Finke; Gerald Illerhaus Journal: Haematologica Date: 2013-01-08 Impact factor: 9.941
Authors: Brian M Nolen; Elizabeth Crabb Breen; Jay H Bream; Frank J Jenkins; Lawrence A Kingsley; Charles R Rinaldo; Anna E Lokshin Journal: PLoS One Date: 2014-06-12 Impact factor: 3.240